The long term goals of this project are to understand the events which regulate the production of myeloid lineage cells from hematopoietic stem cells. Normal, non-infected, humans produce about 2 x 10/9 neutrophils per kilogram of body weight simply to replenish basal neutrophil loss each day. This makes the mass of myeloid precursor cells in the marrow one of the most actively proliferating tissues in the body. The events which regulate proliferation of myeloid cells at all levels are precise, complicated, flexible, and subject to may levels of controls. There is increasing evidence that both humoral and cell-associated cytokines provide much of the regulation of myeloid cell proliferation, influence patterns of differentiation, control traffic of mature and immature cells, and influence functions of mature neutrophils, monocytes, eosinophils & basophils. An interplay between groups of growth-promoting cytokines and growth-inhibitory cytokines helps to determine whether stem cells become committed to the myeloid lineage, whether myeloid precursor cells proliferate or become quiescent, how long it takes to generate a neutrophil from a stem cell, and even how long both precursor cells and neutorphils will live. There are a large number of cytokines which are believed to have a regulatory effect on myelopoiesis, at least in inflammatory situation, including G-CSF, GM-CSF, IL-3, IL-1, IL-5, IL-6, SCF, and others. Over the initial five years of this grant (1984-88), our aims were to identify the major cytokines affecting myelopoiesis and determine their major biological properties first in vitro, and then in vivo in human subjects. Over the last five years of the grant (1989-93), our aims were to identify the receptors for the major myeloid growth factors, begin to understand how these cytokines interact physically with their receptors, and identify the initial elements of receptor signaling. Over the next grant period, we propose to investigate in detail how signals travel from cytokine receptors to the nucleus, how positive and negative signals are integrated in hematopoietic cells, and how these different cytokines and their receptors function together in the context of the whole cell, and ultimately the whole animal, to regulate myelopoiesis. To this end, we will be increasingly using techniques which specifically block or augment selected avenues of signal transduction in intact cells, and later in animals, to dissect the functional pathways of signaling which control hematopoietic cell growth and function. It is anticipated that these studies will result in an improved understanding of how myelopoiesis is regulated at a molecular level. These studies should be further useful in understanding how abnormalities of growth regulatory processes contribute to the pathogenesis of a number of human myeloproliferative disorders such as AML, CML, juvenile CML, polycythemia vera, and marrow failure syndromes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37CA036167-14
Application #
2007425
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1984-03-01
Project End
1999-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
14
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Jiang, Jingrui; Griffin, James D (2010) Wnt/?-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3? Dependent Manner. Genes Cancer 1:164-76
Chen, J; Imanaka, N; Chen, J et al. (2010) Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 102:351-60
Weisberg, E; Ray, A; Barrett, R et al. (2010) Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 24:2100-9
Weisberg, Ellen; Roesel, Johannes; Furet, Pascal et al. (2010) Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer 1:1021-32
Weisberg, Ellen; Choi, Hwan Geun; Ray, Arghya et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115:4206-16
Weisberg, E; Deng, X; Choi, H G et al. (2010) Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24:1375-8
Weisberg, Ellen; Choi, Hwan Geun; Barrett, Rosemary et al. (2010) Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 9:2468-77
Weisberg, E; Sattler, M; Ray, A et al. (2010) Drug resistance in mutant FLT3-positive AML. Oncogene 29:5120-34
Fernandes, Margret S; Reddy, Mamatha M; Gonneville, Jeffrey R et al. (2009) BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 114:1813-9
Weisberg, Ellen; Roesel, Johannes; Bold, Guido et al. (2008) Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 112:5161-70

Showing the most recent 10 out of 119 publications